دورية أكاديمية
Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022.
| العنوان: | Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022. |
|---|---|
| المؤلفون: | Plumb ID; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Mohr NM; Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA., Hagen M; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Wiegand R; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Dumyati G; New York State Emerging Infections Program, University of Rochester Medical Center, Rochester, New York, USA., Harland KK; Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA., Krishnadasan A; Department of Emergency Medicine, Olive View-UCLA Education and Research Institute, Los Angeles, California, USA., Gist JJ; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Abedi G; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Fleming-Dutra KE; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Chea N; National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Lee J; Healthcare-Associated Infections, California Emerging Infections Program, Oakland, California, USA., Barter D; Healthcare-associated Infections / Antimicrobial Resistance Program, Colorado Department of Public Health & Environment, Denver, Colorado, USA., Brackney M; Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA., Fridkin SK; Georgia Emerging Infections Program and Emory University School of Medicine, Atlanta, Georgia, USA., Wilson LE; Maryland Emerging Infections Program, Maryland Department of Health, and University of Maryland, Baltimore County, Baltimore, Maryland, USA., Lovett SA; Infectious Disease Epidemiology, Prevention and Control Divison, Minnesota Department of Health, St. Paul, Minnesota, USA., Ocampo V; Public Health Division, Oregon Health Authority, Portland, Oregon, USA., Phipps EC; New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico, USA., Marcus TM; Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Smithline HA; Department of Emergency Medicine, University of Massachusetts Chan Medical School - Baystate, Springfield, Massachusetts, USA., Hou PC; Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Lee LC; Emergency Medicine, Jackson Memorial Hospital, Miami, Florida, USA., Moran GJ; David Geffen School of Medicine, UCLA, Los Angeles, California, USA., Krebs E; Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA., Steele MT; Department of Emergency Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA., Lim SC; Section of Emergency Medicine, University Medical Center New Orleans, LSU Health Sciences Center, New Orleans, Louisiana, USA., Schrading WA; Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA., Chinnock B; Department of Emergency Medicine, University of California San Francisco, Fresno, California, USA., Beiser DG; Section of Emergency Medicine, University of Chicago, Chicago, Illinois, USA., Faine B; Department of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA., Haran JP; Department of Emergency Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA., Nandi U; Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA., Chipman AK; Emergency Department, University of Washington, Seattle, Washington, USA., LoVecchio F; Emergency Medicine, Valleywise Health Medical Center, Phoenix, Arizona, USA., Talan DA; David Geffen School of Medicine, UCLA, Los Angeles, California, USA., Pilishvili T; National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. |
| المصدر: | Open forum infectious diseases [Open Forum Infect Dis] 2023 Sep 08; Vol. 10 (10), pp. ofad457. Date of Electronic Publication: 2023 Sep 08 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Cary, NC : Published by Oxford University Press on behalf of the Infectious Diseases Society of America, [2014]- |
| مستخلص: | Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant. Methods: We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates. Results: Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants. Conclusions: A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible. Competing Interests: Potential conflicts of interest. M. B. owned stock in Moderna from November 2022 to April 2023, as part of portfolio managed by Parametric Investments Portfolio. All other authors report no potential conflicts. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.) |
| References: | JAMA. 2016 Dec 20;316(23):2547-2548. (PMID: 27792809) MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. (PMID: 35176007) Lancet Rheumatol. 2022 Nov;4(11):e775-e784. (PMID: 35991760) MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1344-1348. (PMID: 34555007) Nat Med. 2021 Oct;27(10):1693-1695. (PMID: 34493859) BMJ. 2022 Mar 2;376:e068632. (PMID: 35236664) MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):416-421. (PMID: 35298454) BMJ. 2022 Jul 6;378:e071502. (PMID: 35793826) Lancet Reg Health Am. 2022 May;9:100198. (PMID: 35187521) BMJ. 2022 Mar 9;376:e069761. (PMID: 35264324) Nat Med. 2022 May;28(5):1063-1071. (PMID: 35189624) Lancet. 2021 Oct 16;398(10309):1407-1416. (PMID: 34619098) Sci Immunol. 2021 Jun 15;6(60):. (PMID: 34131023) Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601) Lancet Rheumatol. 2022 May;4(5):e338-e350. (PMID: 35317410) JAMA. 2022 Feb 15;327(7):619-620. (PMID: 35072715) Sci Immunol. 2022 Apr 22;7(70):eabn8590. (PMID: 35113654) N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272) N Engl J Med. 2022 May 12;386(19):1855-1857. (PMID: 35385628) Vaccine. 2013 Jun 26;31(30):3104-9. (PMID: 23624093) Nat Rev Immunol. 2021 Jun;21(6):395-404. (PMID: 33927374) Lancet Infect Dis. 2022 Sep;22(9):1293-1302. (PMID: 35753318) PLoS Med. 2021 Aug 12;18(8):e1003735. (PMID: 34383750) JAMA Netw Open. 2022 Sep 1;5(9):e2233273. (PMID: 36156146) MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1553-1559. (PMID: 34735426) Am J Epidemiol. 2022 Mar 24;191(5):800-811. (PMID: 35081612) Science. 2022 Mar 11;375(6585):1155-1159. (PMID: 35084938) Lancet Respir Med. 2022 Jul;10(7):689-699. (PMID: 35468336) Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463) MMWR Morb Mortal Wkly Rep. 2022 Jul 22;71(29):931-939. (PMID: 35862287) JAMA. 2021 Aug 24;326(8):728-735. (PMID: 34251417) N Engl J Med. 2022 May 12;386(19):1804-1816. (PMID: 35263534) N Engl J Med. 2021 Oct 7;385(15):1431-1433. (PMID: 34496195) Lancet Respir Med. 2023 Feb;11(2):176-187. (PMID: 36216013) N Engl J Med. 2021 Dec 16;385(25):e90. (PMID: 34551224) Lancet Infect Dis. 2022 Nov;22(11):1553-1564. (PMID: 35964614) Prev Med Rep. 2022 Aug;28:101857. (PMID: 35706687) Nat Rev Immunol. 2022 May;22(5):277-282. (PMID: 35304596) Nat Commun. 2022 May 10;13(1):2414. (PMID: 35538060) Lancet Microbe. 2022 Jan;3(1):e52-e61. (PMID: 34806056) Nat Commun. 2022 Mar 4;13(1):1162. (PMID: 35246536) Epidemiology. 2021 Jul 1;32(4):508-517. (PMID: 34001753) Epidemiology. 2020 Nov;31(6):836-843. (PMID: 32841988) N Engl J Med. 2022 Apr 28;386(17):1603-1614. (PMID: 35417631) JAMA Pediatr. 2021 Aug 1;175(8):817-826. (PMID: 33885740) JAMA Intern Med. 2022 Aug 1;182(8):825-831. (PMID: 35648413) MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753-758. (PMID: 34014909) MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):264-270. (PMID: 35176002) N Engl J Med. 2021 Oct 7;385(15):1355-1371. (PMID: 34496194) |
| معلومات مُعتمدة: | U01 CK000643 United States CK NCEZID CDC HHS; U01CK000480 United States ACL ACL HHS; UL1 TR002537 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: COVID-19; Omicron; SARS-CoV-2; healthcare personnel; vaccine effectiveness |
| تواريخ الأحداث: | Date Created: 20231006 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10549208 |
| DOI: | 10.1093/ofid/ofad457 |
| PMID: | 37799130 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2328-8957 |
|---|---|
| DOI: | 10.1093/ofid/ofad457 |